Type 2 Diabetes: Competitive Landscape to 2026

Type 2 Diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic β-cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle. Insulin is a hormone that regulates the glucose level in blood. Raised blood sugar (hyperglycemia) is an immediate consequence of diabetes, and over time leads to serious tissue damage, affecting the heart, blood vessels, eyes, kidneys, and nerves.

This report provides an assessment of the pipeline, clinical, and commercial landscape of T2D. Overall, GlobalData expects new drug approvals to drive T2D market growth over the next decade (2016–2026).

Scope

GlobalData’s Type 2 Diabetes (T2D): Competitive Landscape to 2026 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

  • Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment—leading marketed products, current and future players
  • Competitive Landscape Analysis—key market events (2016–2026)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Type 2 Diabetes (T2D) market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Type 2 Diabetes (T2D) market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Boehringer Ingelheim

Johnson & Johnson

Eli Lilly

GSK

Takeda

Novartis

AstraZeneca

Merck

Sanofi

Novo Nordisk

Glenmark

Poxel

Intarcia

Pfizer

Theracos

Boehringer Ingelheim

Johnson & Johnson

Eli Lilly

GSK

Takeda

Novartis

AstraZeneca

Merck

Sanofi

Novo Nordisk

Glenmark

Poxel

Intarcia

Pfizer

Theracos

Table of Contents

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 ...

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Definition & Epidemiology Overview

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in T2D

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

5.6 T2D Clinical Trials with CV Outcomes

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2016–2026)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan, China, and India

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports